Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, et al.
Haematologica (2021) Vol. 106, Iss. 8, pp. 2054-2065
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 6, pp. 1265-1274
Open Access | Times Cited: 422
Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy
Mohammed Fatih Rasul, Bashdar Mahmud Hussen, Abbas Salihi, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 114
Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing
Frazer Sinclair, Anjuman Ara Begum, Charles C. Dai, et al.
Drug Delivery and Translational Research (2023) Vol. 13, Iss. 5, pp. 1500-1519
Open Access | Times Cited: 47
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Nico Gagelmann, Danai Dima, Maximilian Merz, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 14, pp. 1665-1675
Open Access | Times Cited: 37
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model
Yu Yang Ng, Zhicheng Du, Xi Zhang, et al.
Cancer Gene Therapy (2021) Vol. 29, Iss. 5, pp. 475-483
Closed Access | Times Cited: 73
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications
Xiaohang Feng, Z Y Li, Yuping Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
Nico Gagelmann, Anna Sureda, Silvia Montoto, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 10, pp. e786-e795
Closed Access | Times Cited: 35
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
Xiang Zhou, Leo Rasche, K. Martin Kortüm, et al.
Haematologica (2022) Vol. 108, Iss. 4, pp. 958-968
Open Access | Times Cited: 34
Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients
Nico Gagelmann, Francis Ayuk, Evgeny Klyuchnikov, et al.
Haematologica (2023) Vol. 108, Iss. 10, pp. 2799-2802
Open Access | Times Cited: 22
Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies
Kamlesh Bisht, Brian A. Walker, Shaji Kumar, et al.
Expert Review of Hematology (2021) Vol. 14, Iss. 12, pp. 1099-1114
Open Access | Times Cited: 24
Allogeneic Stem Cell Transplantation in Multiple Myeloma
Christine Greil, Monika Engelhardt, Jürgen Finke, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 55-55
Open Access | Times Cited: 24
Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo
Xiaojuan Xiao, Zekang Ma, Zhenzhen Li, et al.
Biomaterials (2023) Vol. 297, pp. 122096-122096
Closed Access | Times Cited: 10
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
Laura Gengenbach, Giulia Graziani, Heike Reinhardt, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4320-4320
Open Access | Times Cited: 21
Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells
Marten A. Fischer, Al‐Hassan M. Mustafa, Kristin Hausmann, et al.
Journal of Advanced Research (2023) Vol. 60, pp. 201-214
Open Access | Times Cited: 9
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
Mengying Ke, Liqing Kang, Ling Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 17
BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma
Jiamin Fang, Fuling Zhou
Annals of Hematology (2023) Vol. 103, Iss. 4, pp. 1069-1083
Closed Access | Times Cited: 7
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
Ralph Wäsch, Tim Strüßmann, Claudia Wehr, et al.
Annals of Hematology (2023) Vol. 102, Iss. 5, pp. 1269-1270
Open Access | Times Cited: 6
CRISPR technology in human diseases
Qiang Feng, Qirong Li, Hengzong Zhou, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 2
Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells
Avinoam Reichman, Alexander Kunz, Jara J. Joedicke, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 903-903
Open Access | Times Cited: 10
Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
Jingjing Deng, Yuehui Lin, Defeng Zhao, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 10
Innovation in BCMA CAR-T therapy: Building beyond the Model T
Rahul Banerjee, Sarah S. Lee, Andrew J. Cowan
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 10
Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE
Tatsuya Konishi, Toshiki Ochi, Masaki Maruta, et al.
Blood (2023) Vol. 142, Iss. 21, pp. 1789-1805
Closed Access | Times Cited: 5
Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period
Luis Gerardo Rodríguez‐Lobato, Arturo Pereira, Carlos Fernández de Larrea, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 3, pp. 649-659
Open Access | Times Cited: 11
T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells
Anthony M. Battram, Aina Oliver‐Caldés, María Suárez‐Lledó, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 26, pp. 207-223
Open Access | Times Cited: 7
Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
Hashim Mann, Raymond L. Comenzo
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 799-813
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top